BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...other was a partnership with antibody play Symphogen A/S...
...against up to six targets. The partnership with Symphogen...
...innovative science. What really highlights that is Symphogen...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S...
...for $2.4 billion (see “Servier to Gain Shire’s Cancer Business” ). The deal gives Servier Symphogen’s...
...patients with metastatic colorectal cancer (see “Symphogen’s Sym004 Misses in Phase II for mCRC” ). Symphogen...
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...ApS (Copenhagen, Denmark) and has held roles at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Symphogen A/S...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...therapy Endocrine/ metabolic, hematology, neurology Cell Medica Ltd. $178.1 3/16/17 Off-the-shelf CAR-NKT cell therapies Cancer Symphogen A/S...
BioCentury | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

...Capital, North Sound Capital and Connecticut Innovations. Symphogen looking to raise $86M for antibody platform Symphogen A/S...
...support commercialization of the company's platform for generating therapeutic antibodies for cancer and other diseases. Symphogen...
...options, including spin-offs or a potential sale of the company. Sandi Wong, Staff Writer Applied Therapeutics Inc. IsoPlexis Corp. Symphogen A/S ArcherDx...
BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...Ltd. (Singapore) hired Ivan Horak as president of R&D. He joins the immunotherapy company from Symphogen A/S...
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...CMO. He was chief development officer at PsiOxus Therapeutics Ltd. (Abingdon, U.K.). Cancer antibody company Symphogen A/S...
BioCentury | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

...presented by Symphogen A/S at AACR. A third was published in 2017 by CytoSite BioPharma Inc. Symphogen’s...
...signals from both tracers correlated with response to its PD-1 mAb Sym021 in mouse tumors. Symphogen...
...AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Stanford University, Stanford, Calif. Symphogen A/S...
BioCentury | May 18, 2018
Finance

China comes to Europe

...A) 12/12/16 ADC Therapeutics S.A. $435.0 10/23/17 CureVac AG $320.5 11/8/16 Immunocore Ltd. $320.0 7/16/15 Symphogen A/S...
BioCentury | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...Durham, N.C.) to develop CAR T cell therapies for up to six targets and with Symphogen A/S...
Items per page:
1 - 10 of 111
BioCentury | Jan 29, 2021
Product Development

Servier’s American cancer experiment

...other was a partnership with antibody play Symphogen A/S...
...against up to six targets. The partnership with Symphogen...
...innovative science. What really highlights that is Symphogen...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S...
...for $2.4 billion (see “Servier to Gain Shire’s Cancer Business” ). The deal gives Servier Symphogen’s...
...patients with metastatic colorectal cancer (see “Symphogen’s Sym004 Misses in Phase II for mCRC” ). Symphogen...
BioCentury | Sep 3, 2019
Company News

Management tracks: Tempus brings on former FDA chief of staff; plus Bayer, Genfit, Accent and more

...ApS (Copenhagen, Denmark) and has held roles at Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) and Symphogen A/S...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...therapy Endocrine/ metabolic, hematology, neurology Cell Medica Ltd. $178.1 3/16/17 Off-the-shelf CAR-NKT cell therapies Cancer Symphogen A/S...
BioCentury | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

...Capital, North Sound Capital and Connecticut Innovations. Symphogen looking to raise $86M for antibody platform Symphogen A/S...
...support commercialization of the company's platform for generating therapeutic antibodies for cancer and other diseases. Symphogen...
...options, including spin-offs or a potential sale of the company. Sandi Wong, Staff Writer Applied Therapeutics Inc. IsoPlexis Corp. Symphogen A/S ArcherDx...
BioCentury | Nov 30, 2018
Company News

Management tracks: Inflazome, Clementia

...Ltd. (Singapore) hired Ivan Horak as president of R&D. He joins the immunotherapy company from Symphogen A/S...
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...CMO. He was chief development officer at PsiOxus Therapeutics Ltd. (Abingdon, U.K.). Cancer antibody company Symphogen A/S...
BioCentury | Jun 14, 2018
Tools & Techniques

Imaging immunotherapy

...presented by Symphogen A/S at AACR. A third was published in 2017 by CytoSite BioPharma Inc. Symphogen’s...
...signals from both tracers correlated with response to its PD-1 mAb Sym021 in mouse tumors. Symphogen...
...AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Stanford University, Stanford, Calif. Symphogen A/S...
BioCentury | May 18, 2018
Finance

China comes to Europe

...A) 12/12/16 ADC Therapeutics S.A. $435.0 10/23/17 CureVac AG $320.5 11/8/16 Immunocore Ltd. $320.0 7/16/15 Symphogen A/S...
BioCentury | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...Durham, N.C.) to develop CAR T cell therapies for up to six targets and with Symphogen A/S...
Items per page:
1 - 10 of 111